Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.

The group is aiming for accelerated approval with the upcoming Alpacca trial.

Sunmo succeeds in a setting very similar to Starglo's.

Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.

When your investment case breaks down, why not just do the decent thing?

The registrational part 2 of bezuclastinib's Summit trial reads out in July.